Key result
Three stent thrombosis cases exhibit hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor on thromboelastography.
Case Report (n=3)
This case series demonstrates that functional hyporesponsiveness can occur across all three major P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) in patients experiencing stent thrombosis.
May indicate pan-P2Y12 hyporesponsiveness in stent thrombosis; hypothesis-generating and should not yet change practice.
Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to P 2 Y 12 inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not routine practice to assess the functional response to these agents. However, concern over functional hyporesponsiveness to clopidogrel has led to widespread uptake of prasugrel and ticagrelor as the default P 2 Y 12 inhibitor after stent implantation in patients with acute coronary syndrome. Here we report, for the first time, 3 cases in which patients who have had ST exhibit hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor.
No takes yet. Share an insight, caveat, or question.
Olechowski et al. (2016) conducted a case report in Stent thrombosis (n=3). Short Thromboelastography was evaluated. Three patients with stent thrombosis exhibited functional hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor, assessed using short thromboelastography.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: